<DOC>
	<DOCNO>NCT02501603</DOCNO>
	<brief_summary>For gastric cancer , paclitaxel recommend salvage standard treatment . Afatinib novel , potent , small ErbB family blocker covalently bind irreversibly block signal activated EGFR , HER2 ErbB4 receptor , well transphosphorylation ErbB3 . The investigator suggest randomize phase II trial afatinib plus weekly taxol ( paclitaxel ) previously treat EGFR positive gastric cancer patient . The aim current trial evaluate antitumor efficacy afatinib target enrich patient gastric cancer .</brief_summary>
	<brief_title>Afatinib , Paclitaxel , 2nd Line , Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Histologically cytologically confirm locally advanced metastatic gastric cancer gastroesophageal junction cancer 2 . EGFR 2+ 3+ expression ( immunohistochemistry ) 3 . ECOG performance status 0 1 4 . Male female ; ≥ 19 year age 5 . Documented disease progression one prior therapy , locally advanced metastatic set 6. patient receive last adjuvant chemotherapy less six month enrol study 7 . Her2 positive patient must progress prior trastuzumab base chemotherapy 8 . Subjects measurable lesion ( use RECIST 1.1 criterion ) 9 . Subjects meet follow criterion : Absolute neutrophil count ( ANC ) ≥ 1000 /µL ( *ANC = Neutrophil segs ＋ Neutrophil band ) Platelet count ≥ 80,000/ µL Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) Creatinine clearance ≥50 mL/min use Cockcroft , Gault method AST ( SGOT ) ALT ( SGPT ) : 3 x upper limit normal ( ULN ) ( If Liver Metastasis : 5 x upper limit normal ( ULN ) ) Total bilirubin : 1.5 x upper limit normal ( ULN ) 10 . Provision write informed consent prior study procedure 1 . Any unresolved chronic toxicity great CTC grade 2 previous anticancer therapy . 2 . Any previous chemotherapy immunotherapy within 2 week 3 . Any major operation irradiation within 4 week baseline disease assessment 4 . Two previous systemic cytotoxic chemotherapy ( adjuvant chemotherapy count ) 5 . Any clinically significant gastrointestinal abnormality may impair intake absorption study drug 6 . Previously taxol ( paclitaxel ) expose patient 7 . Subjects symptomatic central nervous system ( CNS ) metastases neurologically unstable require increase dos steroid within 2 week prior study entry manage CNS symptoms 8 . Other coexist malignancy malignancy diagnose within last 3 year exception basal cell carcinoma , thyroid cancer cervical cancer situ . 9 . Subjects uncontrolled major cardiovascular disease ( include AMI within 12 month , unstable angina within 6 month , NYHA class III congestive heart failure , congenital long QT syndrome , 2° AV Block uncontrolled hypertension ) 10 . Pregnant lactate female 11 . Patients contraindicate medication 12 . History interstitial lung disease ( ILD ) presence ILD chest Xray 13 . Evidence significant clinical disorder laboratory find make undesirable patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>